Literature DB >> 16722837

Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

C J Hawkey1, G M Hawkey, S Everitt, M M Skelly, W A Stack, D Gray.   

Abstract

AIMS: Selective cyclooxygenase (COX)-2 inhibitors have recently been implicated as enhancing risk of myocardial infarction (MI). Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are also effective COX-2 inhibitors, so we investigated the hypothesis that they too increase risk of MI.
METHODS: We conducted a case-control study with direct structured interview of cases and controls. Cases were all subjects (N = 205) with a first nonfatal MI who had no previously recognized cardiovascular disease. Community controls (N = 258) were randomly selected from the same practice as the index case. Hospital controls (N = 205) were those admitted at the same time as index cases for nonmyocardial conditions not influenced by NSAID use. The effects of aspirin, NSAIDs and previously recognized influences on MI were investigated by unconditional logistic regression analysis.
RESULTS: NSAID use was associated with an increase risk of MI with an odds ratio of 1.77 (1.03, 3.03) vs. community controls and 2.61 (1.38, 4.95) vs. hospital controls. These values were 5.00 (1.18, 21.28) and 7.66 (0.87, 67.48), respectively, in aspirin users. Results were similar when naproxen was grouped with aspirin. Odds ratios for smoking and for use of antidiabetic medication were 3.91 (2.52, 6.04) and 3.92 (1.25, 12,33), respectively, vs. community controls.
CONCLUSIONS: Like selective COX-2 inhibitors, non-selective NSAIDs [corrected] are associated with an increased risk of MI. The extent to which this reflects interference with aspirin warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722837      PMCID: PMC1885122          DOI: 10.1111/j.1365-2125.2006.02644.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

1.  Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors:  Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

2.  Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.

Authors:  Wayne A Ray; C Michael Stein; Kathi Hall; James R Daugherty; Marie R Griffin
Journal:  Lancet       Date:  2002-01-12       Impact factor: 79.321

3.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Authors:  F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

4.  Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women.

Authors:  L A García Rodríguez; C Varas; C Patrono
Journal:  Epidemiology       Date:  2000-07       Impact factor: 4.822

5.  Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study.

Authors:  Lilja S Jónsdóttir; Nikulás Sigfússon; Vilmundur Gudnason; Helgi Sigvaldason; Gudmundur Thorgeirsson
Journal:  J Cardiovasc Risk       Date:  2002-04

6.  Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Authors:  M A Konstam; M R Weir; A Reicin; D Shapiro; R S Sperling; E Barr; B J Gertz
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

7.  Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

Authors:  Alise S Reicin; Deborah Shapiro; Rhoda S Sperling; Eliav Barr; Qinfen Yu
Journal:  Am J Cardiol       Date:  2002-01-15       Impact factor: 2.778

8.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

9.  Role of prostacyclin in the cardiovascular response to thromboxane A2.

Authors:  Yan Cheng; Sandra C Austin; Bianca Rocca; Beverly H Koller; Thomas M Coffman; Tilo Grosser; John A Lawson; Garret A FitzGerald
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

10.  Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding.

Authors:  W A Stack; J C Atherton; G M Hawkey; R F A Logan; C J Hawkey
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

View more
  5 in total

1.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

2.  Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation.

Authors:  J Andrew Sutton
Journal:  Br J Clin Pharmacol       Date:  2007-04       Impact factor: 4.335

3.  Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Authors:  Hao Qian; Na Luo; Yuling Chi
Journal:  J Aging Res       Date:  2012-02-13

4.  Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence.

Authors:  Wen-Yi Shau; Hsi-Chieh Chen; Shu-Ting Chen; Hsu-Wen Chou; Chia-Hsuin Chang; Chuei-Wen Kuo; Mei-Shu Lai
Journal:  BMC Cardiovasc Disord       Date:  2012-02-02       Impact factor: 2.298

5.  Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.

Authors:  Edwin S L Chan; Hongwei Zhang; Patricia Fernandez; Sari D Edelman; Michael H Pillinger; Louis Ragolia; Thomas Palaia; Steven Carsons; Allison B Reiss
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.